SCHEMBL26879986

SCHEMBL26879986

CCN1CC[C@H](COC)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 4/20 0.41
ALDH1A1 P00352 2/20 0.37
MAPT P10636 1/20 0.37
LMNA P02545 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35
TP53 P04637 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
MAPK1 P28482 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
PMP22 Q01453 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
HRH3 Q9Y5N1 2/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12188157 1.00 CHRM3 (0.41) CHRM3ALDH1A1MAPTLMNANPC1
SCHEMBL21429859 1.00 CHRM3 (0.41) CHRM3ALDH1A1MAPTLMNANPC1
SCHEMBL24792473 0.89 CHRM3 (0.36) CHRM3ALDH1A1MAPTLMNANPC1
SCHEMBL12188159 0.89 SMN1; SMN2 (0.41) ALDH1A1SMN1; SMN2HRH3HTT
SCHEMBL7702796 0.88 NPSR1 (0.40) MAPTRAB9ADRD2DRD3CYP1A2
SCHEMBL17297341 0.84
SCHEMBL20314578 0.83 CHRM3 (0.39) CHRM3SMN1; SMN2DRD2DRD3TP53
SCHEMBL24792222 0.83 CHRM3 (0.39) CHRM3SMN1; SMN2DRD2DRD3TP53
SCHEMBL12335282 0.83 DRD2 (0.40) LMNADRD2DRD3
SCHEMBL21862164 0.82 SMN1; SMN2 (0.36) ALDH1A1SMN1; SMN2HRH3HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023240138-A1 INDAZOLE CONTAINING MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed
US-20230364086-A1 COMBINATION THERAPIES WITH EHMT2 INHIBITORS Epizyme, Inc. 2023-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230364086-A1 COMBINATION THERAPIES WITH EHMT2 INHIBITORS EHMT2, BHMT, SHMT2 CHRM3 4139/4885ALDH1A1 430/4885MAPT 2065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.